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ORIGINAL ARTICLE
Problems, needs and service provision related to stimulant
use in European prisons
TOM DECORTE
Institute for Social Drug Research (ISD), Ghent University, Belgium
Abstract
Objective. The objective of this study was to examine practices and policies in place for the provision of
targeted prevention and treatment of cocaine and Amphetamine Type Stimulant (ATS) users in
prison in nine European countries. Methodology. Across nine European member states (Belgium, the
Netherlands, Czech Republic, Lithuania, Slovenia, Sweden, Malta, Ireland and Portugal), interviews
were conducted with ministerial representatives and professionals (i.e. service providers and security
officials) working in prisons and a total of 16 focus groups with a total of 125 prisoners. Results. The
use of stimulants in prison is associated with aggression and violence, financial problems, and
psychological and physical problems in prisoners (depression, anxiety and psychological craving).
Both security and healthcare staff in prison often feel ill-equipped to deal with stimulant-related
problems, leading to a lack of equivalence of care for stimulant users in prison, therefore the variety
and quality of drug services outside is not reflected sufficiently inside prison. There is a need for more
specific product information and harm reduction material on stimulants, for clear guidelines for the
management of acute stimulant intoxication and stimulant withdrawal, for structural adjustments to
improve potential diagnosis of personality and psychiatric disorders, for more non-pharmacological
treatment strategies and more opportunities for prisoners to engage in purposeful activities.
Keywords: Cocaine, Amphetamine Type Substances, prison, treatment, stimulants
Introduction
Although it is difficult to identify clear-cut European trends due to a lack of a consistent
series of surveys, the available data suggest that consumption of stimulants in the general
community has increased over the last decade. Recent data suggests a stabilisation,
however*Europe has become an important market for the consumption and distribution
of cocaine and cocaine has become a major element in the European drug picture
(UNODC, 2003a, 2004). In both Western and Eastern Europe, drug users reveal a high
level of recreational use of cocaine in several social settings.
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Similarly, consumption of Amphetamine Type Stimulants (the term refers to both the
group of amphetamines and the group of ecstasy drugs) has increased over the last two
decades. Of the amphetamines, amphetamine seems to be by far the most commonly
available in Europe, although, globally, levels of methamphetamine use are increasing
(EMCDDA, 2005; UNODC, 2003b). Among younger users, amphetamines were the
second most popular substance, but during the 1990s they have been overtaken by ecstasy
in practically all European countries (EMCDDA, 2004; UNODC, 2003b).
For some users, the use of these stimulants can become problematic. During the last
decade, cocaine has become more commonly identified (compared to opiates and cannabis)
as the principal drug used by those engaging in drug treatment and accounts for about 10%,
predominately by men, of all treatment demands across Europe. However, the use of
Amphetamine Type Stimulants is still rarely the primary reason for attending drug
treatment (Klee & Morris, 1994).
It is likely that this upward trend in the use of amphetamines and cocaine in the general
population is also reflected in prison populations. Although the provision of substitution
treatment and other harm reduction strategies for prisoners still lags behind the standards
of substitution treatment in the community, the scope of these interventions is extending
gradually across Europe. These strategies, however, are mainly targeted at opiate users. For
users with stimulant problems there seems to be no well-established and widespread
pharmacological treatment available, and overall treatment options for those with cocaine
problems until recently were poorly developed. Nevertheless, new treatment responses
targeting those with cocaine and/or amphetamine problems are being developed, and new
measures and initiatives emphasising the prevention and reduction of health-related harm
caused by the use of cocaine, crack and other stimulants have increased.
The development of services to treat stimulant use in the community raises interesting
and until recently, under-researched issues, such as the presence of cocaine and
Amphetamine Type Stimulant users in prisons, the specific problems and risks associated
with it and how these are addressed.
This paper presents findings from a study into provisions for treating cocaine and
Amphetamine Type Stimulant use in prisons, in nine European countries (funded by the
European Commission and Cranstoun Drug Services/ENDIPP). More specifically, it raises
important questions as to whether these users have specific needs and whether these needs
are being addressed through the existing provisions for treatment and harm reduction in
European prisons.
Background
Data regarding the prevalence of stimulant drug use in prisons are limited and it is therefore
problematic to view this as representative of the actual situation as previous research has
shown that the numbers are by definition an understatement (Knight et al., 1998; Mason
et al., 1997). However, studies have highlighted some important issues for consideration
such as the different type of drug use prevalent in prisons, and the various factors which
explain this. The specific type of drug, e.g. opiates, amphetamines, will often determine the
route of ingestion, such as injecting or smoking. The type of drug used prior to
imprisonment also impacts on drug user behaviour in the prison and studies have shown
that prisoners are more likely to continue to use heroin while in prison, compared to either
cocaine or amphetamines (Keene, 1997; Cope, 2000; Strang et al., 2006). Injecting drug
use seems to be rare within prisons, and this is often attributed to the lack of needles
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available (Long et al., 2004). However, in both the community and in prison there is not
one homogenous subculture of cocaine users or amphetamine users. One can find various
sophisticated typologies of cocaine users or amphetamine users in the international
scientific literature (Cohen, 1989; Waldorf et al., 1991; Mugford, 1994; Erickson et al.,
1994; Decorte & Slock, 2005).
Stimulant use has been identified as more prevalent in pre-trial prisons, or within pre-trial
sections of prisons compared to sentenced prisons (especially on drug-free wings) which is
attributed to the presence of more dealers and the absence of urine testing (Mason et al.,
1997; Brooke et al., 1998). However, studies have also shown that prisoners usually prefer
depressant-type drugs in prison as these can be used more readily to produce relaxation and
to relieve boredom (Swann & James, 1998; Bullock, 2003; Strang et al., 2006).
Users of cocaine and Amphetamine Type Stimulants more often show (or show
symptoms of) personality disorders or psychiatric problems, such as depression, Attention
Deficit Hyperactivity Disorder (ADHD), suicidal tendencies, anxiety disorders, psychotic
behaviour, borderline personality traits (Kleinman et al., 1990; Farrell et al., 2002). At the
same time stimulant users seem to conceive their drug consumption as non-problematical
(Klee & Morris, 1994). The claim for a causal relation between the use of stimulants and
these behavioural problems is hard to prove, as they may be a direct consequence of pre-
existing disorders or pathologies (such as depression, paranoia, psychosis, auto-mutilation
and suicidal tendencies) (Farrell et al., 2002), and/or influenced by the general condition of
overcrowding in prisons (MacDonald, 2004).
Other problems related to stimulant use are (psychological) craving, insomnia and
physical symptoms like heart palpitations, weight loss, exhaustion, hyperthermia, etc.
These physical problems are most significant and acute in remand prisons, during the first
days and sometimes weeks after arrival in prison (Mason et al., 1997; Brooke et al., 1998).
In comparison with those who use heroin as their main drug of choice, amphetamine
users report greater interest in sex and greater frequency of intercourse (Klee, 1993).
Moreover, in many countries amphetamine users are less likely to present themselves to
treatment services, compared to other users. This is related to the perception amongst
amphetamine users that treatment services are primarily oriented toward opiate users and
are usually ill-equipped to deal with amphetamine-related problems (Kamieniecki et al.,
1998).
The problem is that despite the great deal of effort that has been expended in devising
effective treatments for cocaine users, there is no consensus regarding effective treatment
(WHO, 2000). The same is true for amphetamine users (WHO, 2001). However, although
there is a lack of consensus on effective interventions for stimulant users, some
interventions have been found to be more effective than others (Kamieniecki et al., 1998;
Rigter et al., 2004). Harm reduction campaigns targeting stimulant users are sometimes
difficult to evaluate, but they seem successful, especially when members of the target group
are involved in the design of the resources for the campaigns (Kamieniecki et al., 1998). For
the management of acute stimulant intoxication (i.e. management of the toxic complica-
tions in stimulant users usually in emergency departments of hospitals) guidelines have
been devised by clinicians with extensive experience (Kamieniecki et al., 1998). There has
been extensive research on using pharmacological agents to treat stimulant users. Blocking
drugs (lithium, ondansetron) have been largely unsuccessful in treating stimulant users, and
aversive drugs (phenelzyne, tranylcypromine) appear to be too dangerous to use. Drugs to
decrease the discomfort of stimulant withdrawal and craving (such as desipramine,
phenytoin) have demonstrated efficacy in at least some studies, but further research is
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needed. The use of replacement drugs in treating amphetamine users (such as dexamphe-
tamine) appears potentially promising, but most studies have been uncontrolled.
Controlled trials of the prescription of cocaine have indicated that prescribing cocaine
significantly reduced relapse to heavy, illicit cocaine use and reduced cravings for the drug
(Kamieniecki et al., 1998).
The non-pharmacological interventions which have demonstrated the most efficacy in
treating stimulant users are relapse prevention, cue exposure/response prevention,
cognitivebehavioural interventions and possibly multifaceted behavioural treatment.
Other forms of non-pharmacological interventions have not been evaluated properly
(Rigter et al., 2004).
Methodology
The general objective of this study was to examine practices and policies in place for the
provision of targeted prevention and treatment of cocaine and Amphetamine Type
Stimulant users in prison in nine European countries. The specific objectives of this study
were (a) to undertake a review of the national strategies to address Amphetamine Type
Stimulant use for detainees; (b) to examine in detail the policies and the implementation of
services in two sample institutions which address the needs of Amphetamine Type
Stimulant users; (c) to establish the needs of Amphetamine Type Stimulant users in the
two sample institutions; (d) to identify gaps in and barriers to accessing service provision
among Amphetamine Type Stimulant users in the two sample institutions; and (e) to
promote awareness of the initiatives operating in the area of Amphetamine Type Stimulant
use for prisoners.
The study was based on a similar research design as previous studied commissioned by
Cranstoun Drug Services (for example Sto¨ver et al., 2004; MacDonald, 2004; Sto¨ver,
2001), using qualitative methods such as guided interviews and focus groups. Qualitative
methods have proven to be suitable for public health studies and complex contexts as well as
for charting the differing views of those involved. The choice of a qualitative approach
reflects the fact that the drug-related health strategies (especially harm reduction measures)
in prisons are a controversial issue in many countries and require a sensitive approach.
Indeed, qualitative methods are a relevant and useful research tool to reach a deeper
understanding of the phenomenon of drug-related services in prisons, as well as to evaluate
it from the perspective of those involved in it.
This study is therefore not comparative or representative, but explorative. The
researchers were not concerned with testing pre-existing hypotheses. Instead, the focus
was on gaining knowledge, experiences, attitudes and perceptions of different groups
involved in specific health interventions. Using qualitative methods enabled the researchers
to better understand participants’ experiences, views and opinions and present findings
within the context of the settings of the research and the issues raised by it.
The research took place in nine European countries: Belgium, the Netherlands, Czech
Republic, Lithuania, Slovenia, Sweden, Malta, Ireland and Portugal. In each of these
countries, national facilitators were identified through the ENDIPP-network. These
country co-ordinators, usually working in the national prison service, played a key role in
the process of this research. They assisted in collection and, if necessary, translation of
relevant documents, in identification of experts and potential interviewees, in the selection
of two sample prisons for a field visit, and in the general organisation of the fieldwork.
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Between 2005 and 2006 two sample prisons were visited in each country, except Malta.
During each field visit, guided interviews were conducted with ministerial and non-
governmental organisation representatives, and with professionals working in prison from
health and security. These professionals included the drug treatment team (i.e. medical
doctor, psychiatrist and nurse), the psycho-social team (i.e. psychologist, social worker,
pedagogue, educator), guards, management team and the governor and/or deputy
governor. Participants were asked open-ended questions, preferably in face-to-face inter-
views. On two occasions, some participants were interviewed together, according to
available resources and local organisation. Each interview lasted approximately 4575
minutes.
In each prison, prisoners with a history of cocaine or Amphetamine Type Stimulant use
and/or experiences with drug treatment while in prison and/or in the community were
invited to take part in a focus group interview. In addition, a professional involved in
treatment or services for drug users, identified by the ENDIPP national facilitators,
organised the interviews according to the researchers’ requirements, which were commu-
nicated prior to the field visit. Prisoners were interviewed in a neutral room within the
prison and in the sole presence of the researcher. Further to prisoners’ consent, the focus
group interview was tape-recorded for data analysis purpose, and remained in the sole
possession of the researcher. Open-ended questions were asked in focus groups with
prisoners. Focus groups, which included on average 7.8 prisoners per group, lasted
approximately 90 minutes. In total, 16 focus groups in 16 prisons across 8 countries were
conducted, reaching a total number of 125 prisoners.
Participants were interviewed in their native language either directly by the researchers
(in Belgium and the Netherlands, because they spoke the language) or via an interpreter (in
Ireland, Slovenia, Portugal, Sweden, Czech Republic and Lithuania). Participants were
briefed and debriefed on the research goals and ethical issues. Their participation was
voluntary, confidential and anonymous.
Due to time and resource constraints, data on Malta were collected through distant data
collection techniques. These include review of the available data on Malta in databases such
as those produced by the EMCDDA, and library and internet searches. The location of key
stakeholders and staff members from relevant external organisations was also established via
the Internet or obtained through colleagues. On several occasions these participants were
contacted (by e-mail, by telephone, by fax) and invited to supply information on relevant
research questions by e-mail or fax. Distant data collection techniques have obvious
disadvantages, as they can be impersonal and time consuming and exclude the views of
prisoners on service provision, as they cannot be contacted in the same way as staff and
other professionals. Therefore, these are not included within the data from the Maltese
Correctional Facility.
The qualitative data collected through the interviews and focus groups were analysed
using a content analysis method, which generated themes and categories. Because the
results are primarily based on field visits conducted in a limited number of prisons, with a
limited number of participants, the findings are not representative.
Limitations of the present study
It is evident that this study only offers snapshots of the services provided for cocaine and
ATS users in European prisons. Considering the heterogeneity of treatment programmes
across European prisons, the findings provide a limited basis for comparison. Moreover, the
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descriptions obtained during the field visits do not generate a generalised picture of a
country. Instead, they reflect the subjective experience of some individuals involved with
drug-related measures and reflect some specific practices in different prisons and countries.
A qualitative design, such as the one used in this study, does not produce reliable,
comparable and meaningful hard statistics or a quantitative analysis of the prevalence of
drug users in a particular prison, the prevalence of different types of substances (such as
stimulants) in that prison, and*to a lesser extent*the patterns of use of different
substances within that prison setting.
Results
Prevalence of cocaine and Amphetamine Type Stimulant users in prison
Most interviewees in our study report a general increase of stimulants use in prisons. In
some countries, such as the Czech Republic and Sweden, the use of Amphetamine Type
Stimulants is not a very recent phenomenon, but in other countries indirect indicators of
drug use in prison already seem to reflect the general upward trend of stimulant use in the
community. Using or trafficking cocaine or Amphetamine Type Stimulants is an illegal act
in all of the countries in this study (and by extension in all European countries), and thus
subject to criminal justice sanctions. Both in general society and in a prison setting, people
tend to conceal their drug use. Under these conditions, admitting and talking about drug
use to other people is often hindered by a general sense of embarrassment, as using drugs is
perceived by many as a sign of personal weakness, psychological malfunctioning or even a
disease, both outside and inside the prison. Moreover, admitting or talking about drug use
often implies that security staff, medical or social staff will initiate a range of strategies with
the intent of controlling, changing or adjusting the individual’s behaviour. When a person is
not ready or not willing to allow others to interfere or help him/her with drug-related issues,
he/she will prefer to keep the use of any (illegal) drug hidden. As one prisoner noted ‘‘[. . .]
there are a lot of cocaine users here . . . who aren’t here [i.e. in the focus group] because they
fear supervision’’ (Prisoner, Hasselt prison, Belgium).
Even if the number of seizures of stimulants are low in prison and self-reports of cocaine
use by prisoners are rare, this should not automatically lead to the assumption that actual
use of these substances is low. Some of the people interviewed claimed that there was no
need for concern, as the available indicators did not show Stimulant use:
You do not see stimulant use. Cocaine is a big problem on the outside, but does not seem
to have crossed into prison [. . .] They may have used it in the past, maybe in the
community but they do not in prison. Are the prisoners saying that they use in the prison?
(Medical staff, Mountjoy prison, Ireland).
We must add that concepts or categories such as ‘cocaine users’ and ‘speed users’ partly
lose their usefulness, as in most countries, our respondents have indicated that polydrug use
is a widespread phenomenon. Incidences of combined use of opiates (heroin or methadone)
and cocaine, of alcohol and opiates or cocaine, of amphetamines and other drugs and
combinations with cannabis and legal prescription drugs were reported in all countries
involved in this study.
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Routes of ingestion
Cocaine and Amphetamine Type Stimulants show a great diversity in the ways in which
they can be taken. In the general population, snorting is the most widespread method. In
general, most respondents claimed that injecting stimulants in European prisons is rare.
This view was shared by most of the representatives of the National Prison Administrations
of the countries visited and by several staff members in several of the sample prisons. The
two most frequently heard explanations for this are that there are few needles available in
prison and that most prisoners seem to be aware of the risks associated with intravenous use
of drugs (such as the contraction of blood-borne viruses). According to these respondents,
the fact that seizures of needles in prison are rare is proof of the low prevalence of
intravenous use. The fact that cocaine and Amphetamine Type Stimulants can be snorted,
swallowed or in some cases inhaled (‘chasing the dragon’ or ‘freebasing’), seems to be
perceived by prisoners as ‘safer’, even though there are some risks associated with these
methods:
I did a line together with my cell mate. We watched football and had a nice evening. It felt
like an evening out. People think that snorting coke brings a milder crash than smoking
crack. But I don’t like snorting. I always smoke cocaine. And when I got raw cocaine I
make base by myself. Of course ammonia (to make base coke) is hard to get inside*but
then I just took urine*it’s working too. We are real professors in this field (prisoner, PI
Vught, The Netherlands).
This is confirmed by some prisoners, who claim that needles are hard to get and that,
among prisoners, intravenous drug use is perceived as marginal. If inmates do inject, they
tend to do it alone and secretly, or within a very small group of fellow intravenous users.
However, there are indications that in some prisons injecting drugs (including cocaine and
Amphetamine Type Stimulants) is on the rise, or already widespread, according to
prisoners. For some, there is an economic aspect to this route of ingestion: if you inject
drugs you can get more of an effect than if you inhale or sniff it.
Factors influencing stimulant use in prison
The use of stimulants in prison is influenced by many factors. Of course, there may be a
relationship between drug use within prison and the type of drug used prior to
imprisonment, but this is not always an absolute relationship. Our findings suggest that
changes in the drug-taking behaviour of drug users after imprisonment vary according to
the type of drug being taken. Prisoners are more likely to continue to use heroin while in
prison, compared to either cocaine or amphetamines.
An obvious factor which influences cocaine or Amphetamine Type Stimulant use in
prison is availability (or the lack of availability). There is no reason why the smuggling of
stimulant drugs into prisons would be more difficult than that of heroin. According to
prisoners, availability of cocaine and Amphetamine Type Stimulants is higher in remand
prisons or pre-trial sections than in other sections due to the presence of more dealers and
the absence of urine testing and lower in drug-free wings or treatment sections.
Clearly, availability of stimulants in prison is itself influenced strongly by demand factors,
such as the high price. Cocaine is, in most countries, an expensive drug and price levels in
prison are generally higher than in society, as suppliers charge the costs and risks of
smuggling to the consumer. Although the objective price level of a substance is an
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important demand factor, it must be stressed that there is of course an individual element in
the perception of prisoners, according to their financial situation. What is not affordable to
some prisoners, may well be affordable to others. Therefore, some prisoners may have
sufficient resources to pay for cocaine in prison, and some may not. The high price of
stimulants such as cocaine may also cause serious financial problems in prison after a while,
in terms of debts to suppliers:
I see people in prison, they have a lot of money [in] the beginning and they use stimulants
[. . .]. But they spend their money very soon and then there is a crisis, and they sell
everything, the computer, clothes (ex-prisoner of Ljubljana prison in Slovenia).
Another important demand factor influencing the availability of stimulants in prison is
their inappropriateness for a prison environment. As noted by one member of the focus
group, ‘‘Heroin is the prison drug. [. . .] What is the point of being out of your head and
locked in your cell? You would go mad and out of your head on your own’’ (Prisoner,
Dochas Centre, Ireland).
Our interviews suggest that prisoners usually prefer depressant-type drugs in prison as
these can be used more readily to produce relaxation and to relieve boredom. Many outside
users of stimulants become users of opiates, cannabis or depressant prescription drugs in
prison. However, some prisoners stated they would use stimulants in prison, as they ‘make
time go faster’, they are less easily detected (compared to cannabis), they reduce hunger,
and can counter and mask the effects of opiates.
Availability of substances in prison in some countries may also be significantly lower in
institutions for female prisoners. According to some respondents, this is related to ‘better’
drug supply networks in male prisons and the fact that women generally chose different
coping strategies to adapt to prison life.
Many of our interviewees contend that the presence of activities, such as employment,
training facilities, fitness and other leisure activities and the presence of therapeutic
programmes (in drug-free zones), can act as useful alternatives to using drugs. Prisoners
who work, attend educational training, or have sufficient access to leisure facilities tend to
be less interested in using drugs.
Profiles of stimulant users in prison
Some of our respondents suggested that stimulant users in prison tend to be younger
people, with a larger proportion of women. As to the socio-economic backgrounds,
perceptions vary significantly from country to country. Stimulant users are also more likely
to display symptoms of personality disorders or psychiatric problems, but are also less likely
to view their drug use as problematic.
Problems and risks related to stimulant use in prison
The question as to whether the use of stimulants in prisons represents specific problems and
risks is not easy to answer. Many factors related to the prison setting itself intensify feelings
of stress, anxiety and paranoia in most inmates, whether they use drugs or not. Moreover,
the prison population contains a higher proportion of people with psychiatric problems and/
or personality disorders, irrespective of their substance use.
The use of stimulants in prison is often associated with higher levels of aggression,
violence and bullying, and can result in more unpredictable behaviour. The increase in
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violence may also be related to conflicts between prisoners, related to the drug trade and
bargaining and financial disputes (irrespective of the type of drug):
The withdrawal symptoms of heroin are more physical and it’s possible to use medication
to take care of that. I am a pure pervitin user. The withdrawal with amphetamines is more
mental or psychic, anxiety or paranoia (Prisoner, Ry´novice Prison, Czech Republic)
Other problems related to stimulant use are (psychological) craving, insomnia, and
physical symptoms like heart palpitations, weight loss, exhaustion, hyperthermia, etc.
These physical problems are most significant and acute in remand prisons, during the first
days and sometimes weeks after arrival in prison. Several interviewees indicated that these
symptoms might initially be very intensive and problematic and require close follow-up and
assistance from staff, but that these symptoms generally wear off as the prisoner goes
through withdrawal, as the body gains weight and recovers from exhaustion.
In our interviews with prison staff, a high prevalence of psychological symptoms, such as
depression, anxiety, mood swings, paranoia and hallucinations was related to frequent
amphetamine use and use by injection. A considerable proportion of amphetamine users
are clinically depressed (and probably a considerable proportion of prisoners in general),
and the use of stimulants aggravates this problem.
Within prison systems, whose key aims are control, calmness and order, the typical
nervous and hyperactive behaviour of stimulant users is often seen as a difficult aspect to
manage. Some respondents claimed that this is one of the reasons why stimulant users seem
to end up much more frequently in disciplinary or isolation cells.
In addition, many stimulant users in prison do not see themselves as having a drug
problem, in that they do not identify themselves with a subculture of drug users and,
therefore, often refuse help. For security staff, it was found that specifically identifying
stimulant users was difficult and among medical and treatment staff, the main problem
identified was that they lack experience and guidelines in handling stimulant users:
The ones who use opiates, they practically are sure that they have a great risk of becoming
addicts. The ones who use amphetamine somehow believe that it’s not such a
problematic thing and they won’t get addicted (psychologist, Marijampole prison,
Lithuania).
A risk regularly associated with amphetamine use in the international literature, but oddly
enough not mentioned in any of our interviews, is the effects of stimulants upon sexual
activity and a sex life enhanced by these drugs. A large proportion of these users also engage
in unprotected sex, increasing the risk of HIV infection, and infection with sexually
transmittable diseases. The fact that this issue was never mentioned during our fieldwork
may indicate several things. First of all, it may illustrate the taboo on sexual activity within
prisons. Second, it may illustrate the lack of awareness among staff and prisoners related to
the links between stimulant use and sexual risk behaviour. Third, there is very little
information on the effect of stimulant use in a prison setting on sexual interest and sexual
activity. For some users, the prison setting itself may decrease the interest in sex, but not the
interest in drugs.
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Needs of prisoners and staff regarding stimulant use
First of all, there is a need for more specific information on stimulants, both for security and
treatment staff, in order to help them recognise use of these substances among prisoners
and address associated problems. There is also a need for specific, non-judgmental and
useful harm reduction material for prisoners*for example, to increase knowledge
regarding needle cleaning procedures, methods of minimising ‘comedown’, managing
symptoms of withdrawal, the importance of sleep and good diet, the need to avoid
dehydration, the dangers of combined use or polydrug use and measures to prevent
overdoses, particularly on release from prison.
Both prison hospital staff and medical staff in the sample prisons highlighted the need for
guidelines about the management of acute amphetamine and cocaine intoxication, based on
literature and the experience of leading clinicians and healthcare services in the field.
Many of the physical and psychological problems reported above are most acute when
these users arrive in prison (in remand prisons for example) and when these users go
through some weeks of detoxification. Medical and healthcare staff should be provided with
detailed guidelines for the management of stimulant withdrawal, as this can be very
different to that of opiate withdrawal. This should include guidelines regarding the use of
benzodiazepines and antipsychotic agents, but the use of these medications on their own is
insufficient to deal with stimulant withdrawal. Strategies other than pharmacotherapy, such
as organising support, non-pharmacological means of coping with cravings, tips to improve
sleep, relaxation techniques, coping with mood swings, aches and pains, eating properly,
concentrating only on the immediate future and so on, may each work to some extent:
There’s no help for cocaine users; if you’re a heroin user, you get methadone and then
you’re ok, you’re minding your own business but if you’re cocaine user, you can’t get
anything because they don’t know what to give you. They don’t even give sedatives
(Prisoners, Ljubljana prison, Slovenia).
Many of our respondents complained about the lack of a substitution therapy similar to
methadone for opiate users. Pharmacological agents (such as blocking drugs, aversive drugs
and replacement drugs) have been used in the past to treat stimulant users, but the efficacy
of these products is controversial (see below).
Some stimulant users in prison are ‘walking bombs’ in the sense that they have very
complex psychiatric problems, which are sometimes not diagnosed. There is a need to make
structural adjustments to improve potential diagnosis of personality and psychiatric
disorders and to provide adjusted guidance in specific detention settings or specialised
prison sections.
However, the most commonly identified gap in provisions for stimulant users is the need
for strategies that surpass the basic medical or product-oriented approach, including
psychological support. Many prisoners expressed that this was a greater need compared to
simply providing more medication, in order to address the psychological dependence, and
the psychosocial aspects of their drug-taking behaviour. There is also a need for staff to be
better trained in recognising stimulant-related problems and in more appropriate ways of
reacting towards the problems mentioned earlier.
Finally, many prisoners use drugs to relieve boredom and to kill time. There is clearly
a need for a more meaningful prison regime, in which prisoners are kept busy, through
work, training, education and leisure activities. The views of staff and prisoners for a
more meaningful imprisonment and for more psychosocial assistance (rather than
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product-oriented strategies) also demonstrates the in-appropriateness of imprisoning
problematic drug users, as within this setting, the range of strategies needed to treat drug
use are not widely available.
Targeted interventions in prison
In this study almost no targeted interventions towards stimulant users in prison were found.
In several countries, staff members and representatives suggested the issues of cocaine use
or amphetamine use had come up in group sessions or in individual counselling, or in
information sessions by external organisations. However, when these interviewees were
asked for more details on the nature and the extent of these sessions, no evidence for a
systematic, guided approach towards stimulant users was found. None of the prisoners
acknowledged the existence of targeted interventions towards stimulant users. In those
countries with explicit national drug policies in prison, no differentiation is made between
stimulants and opiates. And even in those countries that have a ‘tradition’ of higher
prevalence of amphetamine use, no targeted or very specific interventions were uncovered.
A claim made by several respondents to explain the lack of targeted interventions towards
stimulant users was that there are no targeted interventions in the community either. In
many countries this seems an acceptable argument, as most provisions and services offered
by local NGOs and treatment centres are not differentiated for opiate users and stimulants
users, or (in the case of substitution treatment for example) mainly targeting opiate users.
Conclusions and recommendations
The use of cocaine and Amphetamine Type Stimulants in prison does raise some concerns,
even if the available indicators do not show an increase. Their use is associated with
aggression and violence, financial problems and psychological and physical problems in
prisoners. Additionally, prison staff (both medical and security staff) often feel ill-equipped
to deal with stimulant-related problems. These conditions are detrimental to the health of
these prisoners and increase the risk of HIV transmission, encourage drug use in response
to boredom or stress and increase stress among inmates, which negatively affects their
mental health, or exacerbates pre-existing mental health problems. Both in the community
and in prison there is not one homogenous subculture of cocaine users or amphetamine
users. One can find various sophisticated typologies of cocaine users or amphetamine users
in the international scientific literature (Cohen, 1989; Waldorf et al., 1991; Mugford, 1994;
Erickson et al., 1994; Decorte & Slock, 2005), and from our interviews, it became clear that
one can find various types of users in prison as well.
The reasons given for the lack of targeted efforts for stimulant users were related to
barriers and problems that hinder the provision of services and harm reduction strategies in
prison in general. Many of these barriers and problems have been identified in several
previous studies, such as the lack of evidence-based policies, the one-sided and unilateral
focus on supply reduction, budget constraints, the over-incarceration of drug users, the
general negative attitude towards drug users, staff shortage, qualifications and training of
security staff and healthcare staff, the need for multidisciplinary action, the suspicion
towards and therefore lack of structural agreements with outside drug service providers
(NGOs) and overcrowding within prisons (MacDonald, 2004). Another factor hampering
the development of targeted interventions towards stimulant users is that much of the
intervention literature for stimulant users has come from the United States and has
primarily involved cocaine users. However, many types of interventions have been
Provisions for stimulant users in prisons 39
D
ow
nl
oa
de
d 
By
: [
U
ni
ve
rs
ite
it 
G
en
t] 
At
: 1
6:
30
 3
0 
M
ar
ch
 2
00
7 
conducted with stimulant users, including preventive interventions and the provision of
harm reduction information, the management of acute stimulant intoxication, withdrawal
management, pharmacological and non-pharmacological treatments and interventions for
stimulant users with co-morbid psychiatric disorders.
The principle of equivalence means that the healthcare measures (medical, psychiatric
and psychosocial) successfully proven and applied outside prison should also be applied
inside prison. Prisoners are entitled, without discrimination, to a standard of healthcare
equivalent to that available in the outside community, including preventive measures. This
principle of equivalence is fundamental to the promotion of human rights and best health
practice within prisons, and is supported by international guidelines on prison health and
prisoners’ rights (by the United Nations, the World Health Organization and UNAIDS), as
well as national prison policy and legislation in many countries.
With regard to support for drug-using inmates, and especially cocaine- and Ampheta-
mine Type Stimulant-using inmates, and to those with underlying personality disorders and
psychiatric problems, the principle of equivalence is still wishful thinking. Differentiation
and quality of drug services outside is not reflected sufficiently inside prison. General
barriers to implementation of effective prison healthcare strategies have been described and
identified a long time ago and in various other studies. It is clear that a lot needs to be done
to make imprisonment more than a punitive institution. If reintegration of prisoners in
general, and drug users in prison in particular, is truly an objective and a function of our
prison systems, then these barriers and problems in organising healthcare in prison need to
be tackled in a much more convincing way.
In our interviews with prison staff a high prevalence of psychological symptoms, such as
depression, anxiety, mood swings, paranoia and hallucinations was related to frequent
amphetamine use, and use by injection (see also: Louie et al., 1989; Kleinman et al., 1990;
Hall & Hando, 1994a,b). A considerable proportion of amphetamine users are clinically
depressed (and probably a considerable proportion of prisoners in general), and the use of
stimulants aggravates this problem. Some prisoners have experiences of psychological
symptoms prior to their initiation to stimulant use, but most of these symptoms increase in
prevalence after the onset of stimulant use (Farrell et al., 2002).
In many countries, a significant percentage of the prison population is comprised of
individuals who are convicted of offences directly related to their own drug use (i.e. those
incarcerated for the possession of small amounts of drugs for personal use, those convicted
of petty crimes specifically to support drug habits). The incarceration of significant
numbers of drug users increases the likelihood of drug use inside prisons and, therefore, an
increase in unsafe injecting practices and the risk of HIV-transmission. Drug users do not
belong in prison, and prison settings are not the ideal setting for drug treatment. Action
should be taken to reduce prison populations and prison overcrowding, as an integral
component of a comprehensive strategy to improve prison healthcare towards drug users
(including stimulant users). Legislative and policy reforms should be pursued to change
criminal law and penalties with the objective of reducing the criminalisation of non-violent
drug offences and significantly reducing the use of incarceration for non-violent drug users.
In order to reduce the number of drug users sent to prison, the overall prison population
and the levels of prison overcrowding, alternatives to prison and non-custodial diversions
for people convicted of offences related to drug use should be developed.
If imprisonment itself cannot be avoided, then treatment and preventive steps have to be
taken from the first day of imprisonment (Sto¨ver, 2001). That includes comprehensive
medical care of withdrawal symptoms from stimulant use, as well as access to health and
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social workers both from inside prison and from community services in order to define
individual problems and disorders. With regard to medical treatment, increased efforts
need to be undertaken in prisons to ensure that (stimulant) using prisoners receive care,
support and treatment equivalent to that available in the community. Prisoners suffering
from withdrawal symptoms (among others from stimulants) should have equal access to
narcotics routinely given for pain relief, reduction of anxiety and paranoia to patients
outside. Prisoners should be allowed equal access to investigational drugs and non-
conventional therapies for stimulant users outside. There is also a need to address problems
associated with dual diagnosis, i.e. drug users who are also identified as having mental
health problems, through the development of adjusted guidance in specialised detention
settings. Inmates should have access to voluntary treatment options that exist in the
community, such as relapse prevention, cue exposure/response prevention, cognitive-
behavioural interventions and multifaceted behavioural treatment. The claim made by
Sto¨ver (2001) is still relevant, in that correctional healthcare needs to evolve from a reactive
sick-call system to a proactive system emphasising early detection of personality disorders
and psychiatric problems, health promotion among drug users, and prevention.
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